Press Releases

Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck's KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1 - Merck & Co (NYSE:MRK)

Merck & Co

Updated Data from KEYNOTE-024 Show Continued Overall Survival Benefit of Merck's KEYTRUDA® (pembrolizumab) Compared to Chemotherapy in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with High Levels of PD-L1

MNMD

TSX:NUMI


-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York


(BRK.A; BRK.B) – Berkshire&#39;s operating results for the first quarters of 2024 and 2023 are summarized in the following paragraphs. However, we urge investors and reporters to read our 10-Q, which has been posted at

Berkshire Hathaway Inc. First Quarter 2024 Earnings Release


Doctoral Journey Colloquium brings together students, faculty and facilitates networking and support opportunities


University of Phoenix College of Doctoral Studies hosted an in-person Doctoral Journey Colloquium

University of Phoenix College of Doctoral Studies Holds Third Annual Colloquium Supporting Doctoral Students

INTC

INTC CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Intel Corporation

KGEI

TSX:KEI


Kolibri Global Energy Inc. (the &#34;Company&#34;) announces that, further to the Company&#39;s news released date May 2, 2024, the Company has completed the filing of the Company&#39;s annual information form, annual audited